21:18 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Mouse studies identified nine...
22:18 , Oct 10, 2017 |  BC Extra  |  Clinical News

AnaptysBio shares double on atopic dermatitis data

AnaptysBio Inc. (NASDAQ:ANAB) gained $35.41 (101%) to $70.41 on Tuesday after reporting data from a Phase IIa trial of lead program ANB020 , an antibody against IL-33, to treat atopic dermatitis. An AnaptysBio spokesperson told...
19:38 , Apr 11, 2017 |  BC Week In Review  |  Clinical News

ANB019: Ph I started

AnaptysBio began a double-blind, placebo-controlled, Australian Phase I trial to evaluate subcutaneous and IV ANB019 in 72 healthy volunteers and 15 patients with plaque psoriasis. Volunteers will receive single doses of 100 mg subcutaneous ANB019...
01:19 , Jul 16, 2015 |  BC Extra  |  Financial News

AnaptysBio raises $40M in series D

Antibody play AnaptysBio Inc. (San Diego, Calif.) raised $40 million in an oversubscribed series D round. BVF Partners and its affiliates; Cormorant Asset Management; Frazier Healthcare; HBM Healthcare Investments; Longwood Capital Partners; and Novo A/S...
01:06 , Apr 17, 2015 |  BC Extra  |  Clinical News

AnaptysBio plans study of first-in-class IL-36R antagonist

Antibody platform company AnaptysBio Inc. (San Diego, Calif.) began IND-enabling studies of first-in-class IL-36R antagonist ANB019 to treat generalized pustular psoriasis (GPP), a rare but life-threatening inherited form of psoriasis for which there are no...
07:00 , Apr 16, 2015 |  BC Innovations  |  Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...